• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»advanced prostate cancer

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

By Pallavi Madhiraju on May 18, 2026   Pharma & Biotech  

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe

By Pallavi Madhiraju on March 8, 2026   Pharma & Biotech  

Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe

CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.

Recent Posts

  • Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes